• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 15,516 units of Ordinary Shares, decreasing direct ownership by 10% to 135,668 units (SEC Form 4)

    2/5/25 6:16:31 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Nath Kabir

    (Last) (First) (Middle)
    C/O COMPASS PATHWAYS PLC
    33 BROADWICK STREET

    (Street)
    LONDON X0 W1F 0DQ

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    COMPASS Pathways plc [ CMPS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 02/03/2025 F 15,516(2) D $4.31 135,668 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
    2. Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations.
    Remarks:
    /s/ Meredith Prithviraj by Power of Attorney for Kabir Nath 02/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    10/29/2021$50.00Outperform
    Oppenheimer
    More analyst ratings

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We

      5/14/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

      Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. "We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal

      5/8/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:35:16 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:20:24 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by COMPASS Pathways Plc

      SC 13G - COMPASS Pathways plc (0001816590) (Subject)

      4/11/24 4:04:21 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by COMPASS Pathways Plc

      SCHEDULE 13G - COMPASS Pathways plc (0001816590) (Subject)

      5/15/25 8:00:10 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:39:09 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by COMPASS Pathways Plc

      10-Q - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:38:40 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Lori Englebert as Chief Commercial Officer

      New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

      6/26/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Teri Loxam as Chief Financial Officer

      LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

      12/7/23 7:00:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Financials

    Live finance-specific insights

    See more
    • Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

      4/28/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

      Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

      2/18/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

      Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progres

      10/31/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on COMPASS Pathways with a new price target

      Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

      2/27/25 6:17:48 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on COMPASS Pathways with a new price target

      RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

      7/23/24 6:23:14 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on COMPASS Pathways with a new price target

      Morgan Stanley initiated coverage of COMPASS Pathways with a rating of Overweight and set a new price target of $30.00

      4/1/24 7:29:23 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Goodwin Guy

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:58 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Loxam Teri was granted 25,000 units of Ordinary Shares, increasing direct ownership by 43% to 83,250 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:29 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nath Kabir was granted 92,000 units of Ordinary Shares, increasing direct ownership by 68% to 227,668 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:14:56 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care